IMMUNOLOGY Brad Frankum, Monique Wei Meng Lee and Jessie a Lee

Total Page:16

File Type:pdf, Size:1020Kb

IMMUNOLOGY Brad Frankum, Monique Wei Meng Lee and Jessie a Lee CHAPTER 16 IMMUNOLOGY Brad Frankum, Monique Wei Meng Lee and Jessie A Lee –Sjögren’s syndrome (SS) CHAPTER OUTLINE –Infl ammatory myopathies –Anti-synthetase syndrome • KEY CONCEPTS IN IMMUNOBIOLOGY –Scleroderma and CREST syndrome – Innate and adaptive immunity –Mixed connective tissue disease (MCTD) –Specifi city and diversity –Antiphospholipid syndrome (APS) –Immunological memory – IgG4-related disease –Hypersensitivity, autoimmunity and immunodefi ciency • PRIMARY VASCULITIS – Immunity, infl ammation and tissue repair – Large-vessel vasculitis –Understanding immunobiology –Medium-vessel vasculitis – Manipulation of the immune system –Small-vessel vasculitis – Single-organ vasculitis • ALLERGIC DISEASE –Variable-vessel vasculitis –Anaphylaxis – Allergic rhinitis (AR) and allergic • AUTOINFLAMMATORY DISORDERS conjunctivitis (AC) – Familial Mediterranean fever (FMF) –Chronic rhinosinusitis – TNF-receptor-associated periodic syndrome – Atopic dermatitis (AD) (TRAPS) – Food allergy • IMMUNODEFICIENCY –Urticaria and angioedema – Drug allergy –Primary immunodefi ciency – Insect venom allergy –Secondary (acquired) immunodefi ciency • EOSINOPHILIA • HIV/AIDS –Hypereosinophilic syndrome (HES) –Epidemiology – Risk factors for HIV infection • MAST CELL DISORDERS – Pathophysiology –Cutaneous mastocytosis (CM) – Clinical features and diagnosis –Systemic mastocytosis (SM) –Management –Prognosis • SYSTEMIC AUTOIMMUNE DISEASE – Systemic lupus erythematosus (SLE) 507 Essentials of internal medicine KEY CONCEPTS IN mechanisms such as coughing, sneezing, urination, and mucus production. IMMUNOBIOLOGY • The innate immune response is rapid, fi rst- line, and prevents tissue invasion in most instances. • Innate and adaptive immunity are unique but heavily interdependent entities. • Epithelial surfaces also provide chemical barriers to infection in the form of secreted antimicrobial peptides, • Specifi city and diversity are the foundation for success- antibacterial enzymes and fatty acids, as well as microbio- ful adaptive immunity. logical barriers in the form of commensal microbiota that • Immunological memory is the basis for immunity and compete with pathogens. immunization. • Phagocytic cells can recognize a restricted number of • Hypersensitivity, autoimmunity and immuno defi ciency cell- surface molecules on microbial pathogens, and are the key drivers of immunopathology. be directly activated. These molecules are known as • Immunity, infl ammation and tissue repair are essential pathogen- associated molecular patterns (PAMPs). and interdependent components of a complex system to Examples of receptors that can recognize PAMPs include maintain health. Toll- like receptors, and mannose- binding lectin (MBL). • Understanding immunobiology is the key to logical • There are also receptors in the cytoplasm of cells that can diagnosis and treatment of infection. recognize microbial products. This is obviously important • Manipulation of the immune system is central to the for dealing with pathogens that have evaded defense mech- current, and future, treatment of a vast range of human anisms in the extracellular environment. Examples include diseases: allergy, autoimmunity, malignancy, infection NOD- like and RIG- 1- like receptors and MDA-5. and transplantation. • The innate immune system also recognizes molecules released from damaged or infected cells. These mol- Innate and adaptive immunity ecules are known as DAMPs, or damage- associated Innate and adaptive immunity are unique but heavily inter- molecular patterns. dependent entities. Their key features are described in » DAMPs help to activate both the innate immune Table 16- 1. response and the infl ammatory response. • Complement is a set of plasma proteins that form a cas- Innate immune response cade to ensure amplifi cation of both innate and adaptive Innate immunity refers to that section of the immune system immune responses. that does not require specifi c antigen recognition to elimi- » Complement can be activated by the presence of nate a pathogen. It includes barrier functions such as integ- microbial cell surfaces, by the presence of immune rity of the skin and mucous membranes, and physiological complexes, or by the binding of MBL. Table 16-1 Innate versus adaptive immunity KEY FEATURES INNATE IMMUNE SYSTEM ADAPTIVE IMMUNE SYSTEM Cells Neutrophils, monocyte-macrophages, eosinophils, B and T lymphocytes, plasma cells basophils, mast cells, dendritic cells, natural killer cells Receptors PRRs, Toll-like receptors B-cell receptors (immunoglobulins), T-cell receptors Eff ectors Molecular—complement, acute phase reactants, cytokines Humoral—B cells, antibody Cellular—phagocytes (neutrophils, monocyte- Cell-mediated—cytotoxic T cells macrophages), cells that produce infl ammatory mediators (eosinophils, basophils, mast cells), natural killer cells Specifi city Absent Antigen-specifi c Memory Absent (does not require prior contact) Antigen-specifi c (requires prior contact) Response time Immediate Delayed Response Not enhanced by prior contact Enhanced by prior contact magnitude PRR, pattern-recognition receptor. 508 Chapter 16 Immunology » Activated complement proteins have chemotactic actions to trigger phagocytosis, as well as eff ector Box 16-1 function, resulting in cell killing through the mem- The fi ve stages of the adaptive brane attack complex. immune response Activation of the innate immune response results in recruit- ment of the adaptive response. This is achieved predominantly 1 Antigen capture via antigen presentation by dendritic cells and macrophages to 2 Recognition of antigen lymphocytes, but is augmented by changes in cytokine milieu. 3 Activation of lymphocytes In turn, the adaptive immune response utilizes eff ector cells of the innate system. 4 Antigen elimination 5 Decline of immune response Adaptive immune response The three key components of the adaptive immune response are diversity, specifi city and memory. » are the cells which recognize self- antigen, so are • Diversity is manifested by the deliberate generation of antigen- specifi c, but develop in such a way as to many lymphocyte clones, but selecting only those that suppress response toward self- antigen rather than recognize foreign but not self- antigen for survival. initiate it • Specifi city refers to each lymphocyte clone having » function to maintain self- tolerance and suppress receptors of one specifi city, and responding to that infl ammatory responses. specifi c antigen only. The adaptive immune response proceeds through the fi ve • Memory is maintained by retention of antigen- specifi c stages listed in Box 16- 1. clones of both B and T lymphocytes, and the ongoing The major histocompatibility complex (MHC) is a set of production of specifi c antibody, in perpetuity. genes which encode for cell- surface proteins that represent a critical step in presenting foreign antigen to the eff ector cells A number of diff erent cells are involved (Figure 16- 1): of the immune system. • B cells diff erentiate into plasma cells to secrete antibody. • Cells which are able to stimulate CD8+ cytotoxic T • CD4+ T- helper cells direct other cells to perform cells must be able to process cytosolic antigen, and pres- eff ector functions. ent the antigen to the cell surface in conjunction with • CD8+ cytotoxic T cells, when activated, kill cells MHC class I antigens. These are all nucleated cells. infected by intracellular organisms, e.g. viruses. • Cells which are able to present antigen to CD4+ T- helper • T- regulatory cells: cells, and stimulate them, must be able to process endo- » are a subset of CD4+ T cells which express high lev- cytosed antigen, and express MHC class II antigens els of CD25, and a transcription factor called FoxP3 in conjunction with the foreign antigen on the cell sur- » are generated centrally in the thymus, or peripher- face. These are dendritic cells, monocyte-macrophages ally in secondary lymphoid tissue and B lymphocytes, and are collectively referred to as antigen- presenting cells. Specifi city and diversity Specifi city and diversity are the foundation for successful Adaptive adaptive immunity. immune system • During development in the bone marrow (B cells) and the thymus (T cells), millions of diff erent genetic recombinations occur in the genes that encode for lym- APC Lymphocytes phocyte receptors. • Immunological specifi city refers to the ability of the immune system to possess cells that are capable of rec- ognizing one specifi c antigen only. This is the function T cells B cells of the lymphocyte. CD3 CD19, CD20 » B lymphocytes express cell- surface receptor (immu- noglobulin) which is specifi c for one antigen. When secreted, this immunoglobulin can be arranged as a pentamer (IgM), dimer (IgA) or monomer (IgG, T-helper T cytotoxic T reg IgE, IgD), but still remains specifi c for one antigen CD3, CD4 CD3, CD8 only. » T lymphocytes express the T- cell receptor which is Figure 16-1 Cells of the adaptive immune system. also specifi c for one antigen only. APC, antigen-presenting cell; T reg = T-regulatory • Immunological diversity refers to the capacity of cell the immune system to have lymphocytes capable of 509 Essentials of internal medicine recognizing every conceivable antigen. The vastness of –Eff ector T lymphocytes are either cytotoxic this repertoire is staggering. T lymphocytes or T-helper cells. » In generating suffi cient diversity amongst the lym- –Eff ector B lymphocytes are plasma cells, which phocyte population, the immune system needs a secrete antibody. system
Recommended publications
  • BAFF-Neutralizing Interaction of Belimumab Related to Its Therapeutic Efficacy for Treating Systemic Lupus Erythematosus
    ARTICLE DOI: 10.1038/s41467-018-03620-2 OPEN BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus Woori Shin1, Hyun Tae Lee1, Heejin Lim1, Sang Hyung Lee1, Ji Young Son1, Jee Un Lee1, Ki-Young Yoo1, Seong Eon Ryu2, Jaejun Rhie1, Ju Yeon Lee1 & Yong-Seok Heo1 1234567890():,; BAFF, a member of the TNF superfamily, has been recognized as a good target for auto- immune diseases. Belimumab, an anti-BAFF monoclonal antibody, was approved by the FDA for use in treating systemic lupus erythematosus. However, the molecular basis of BAFF neutralization by belimumab remains unclear. Here our crystal structure of the BAFF–belimumab Fab complex shows the precise epitope and the BAFF-neutralizing mechanism of belimumab, and demonstrates that the therapeutic activity of belimumab involves not only antagonizing the BAFF–receptor interaction, but also disrupting the for- mation of the more active BAFF 60-mer to favor the induction of the less active BAFF trimer through interaction with the flap region of BAFF. In addition, the belimumab HCDR3 loop mimics the DxL(V/L) motif of BAFF receptors, thereby binding to BAFF in a similar manner as endogenous BAFF receptors. Our data thus provides insights for the design of new drugs targeting BAFF for the treatment of autoimmune diseases. 1 Department of Chemistry, Konkuk University, 120 Neungdong-ro, Gwangjin-gu, Seoul 05029, Republic of Korea. 2 Department of Bio Engineering, Hanyang University, 222 Wangsimni-ro, Seongdong-gu, Seoul 04763, Republic of Korea. These authors contributed equally: Woori Shin, Hyun Tae Lee, Heejin Lim, Sang Hyung Lee.
    [Show full text]
  • Ocrevus (Ocrelizumab) Policy Number: C11250-A
    Prior Authorization Criteria Ocrevus (ocrelizumab) Policy Number: C11250-A CRITERIA EFFECTIVE DATES: ORIGINAL EFFECTIVE DATE LAST REVIEWED DATE NEXT REVIEW DUE BY OR BEFORE 8/1/2017 2/17/2021 4/26/2022 LAST P&T J CODE TYPE OF CRITERIA APPROVAL/VERSION J2350-injection,ocrelizumab, Q2 2021 RxPA 1mg 20200428C11250-A PRODUCTS AFFECTED: Ocrevus (ocrelizumab) DRUG CLASS: Multiple Sclerosis Agents - Monoclonal Antibodies ROUTE OF ADMINISTRATION: Intravenous PLACE OF SERVICE: Specialty Pharmacy or Buy and Bill The recommendation is that medications in this policy will be for pharmacy benefit coverage and the IV infusion products administered in a place of service that is a non-hospital facility-based location (i.e., home infusion provider, provider’s office, free-standing ambulatory infusion center) AVAILABLE DOSAGE FORMS: Ocrevus SOLN 300MG/10ML FDA-APPROVED USES: Indicated for the treatment of: • Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing- remitting disease, and active secondary progressive disease, in adults • Primary progressive MS, in adults COMPENDIAL APPROVED OFF-LABELED USES: None COVERAGE CRITERIA: INITIAL AUTHORIZATION DIAGNOSIS: Multiple Sclerosis REQUIRED MEDICAL INFORMATION: A. RELAPSING FORMS OF MULTIPLE SCLEROSIS: 1. Documentation of a definitive diagnosis of a relapsing form of multiple sclerosis as defined by the McDonald criteria (see Appendix), including: Relapsing- remitting multiple sclerosis [RRMS], secondary-progressive multiple sclerosis [SPMS] with relapses, and progressive- relapsing multiple sclerosis [PRMS] or First clinical episode with MRI features consistent with multiple sclerosis Molina Healthcare, Inc. confidential and proprietary © 2021 This document contains confidential and proprietary information of Molina Healthcare and cannot be reproduced, distributed, or printed without written permission from Molina Healthcare.
    [Show full text]
  • Aeroallergen-Induced Th2 Inflammation Endogenous And
    Endogenous and Exogenous IL-6 Inhibit Aeroallergen-Induced Th2 Inflammation Jingming Wang, Robert J. Homer, Qingsheng Chen and Jack A. Elias This information is current as of September 26, 2021. J Immunol 2000; 165:4051-4061; ; doi: 10.4049/jimmunol.165.7.4051 http://www.jimmunol.org/content/165/7/4051 Downloaded from References This article cites 61 articles, 22 of which you can access for free at: http://www.jimmunol.org/content/165/7/4051.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on September 26, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2000 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Endogenous and Exogenous IL-6 Inhibit Aeroallergen-Induced Th2 Inflammation1 Jingming Wang,* Robert J. Homer,† Qingsheng Chen,* and Jack A. Elias2* Chronic Th2-dominated inflammation and exaggerated IL-6 production are characteristic features of the asthmatic airway. To understand the processes that are responsible for the chronicity of this response and the role(s) of IL-6 in the regulation of airway Th2 inflammation, we compared the responses induced by OVA in sensitized wild-type mice, IL-6 deficient (؊/؊) mice, and transgenic mice in which IL-6 was overexpressed in the airway (CC10-IL-6 mice).
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group R01 (Nasal preparations) Table of Contents Page INTRODUCTION 5 DISCLAIMER 7 GLOSSARY OF TERMS USED IN THIS DOCUMENT 8 ACTIVE SUBSTANCES Cyclopentamine (ATC: R01AA02) 10 Ephedrine (ATC: R01AA03) 11 Phenylephrine (ATC: R01AA04) 14 Oxymetazoline (ATC: R01AA05) 16 Tetryzoline (ATC: R01AA06) 19 Xylometazoline (ATC: R01AA07) 20 Naphazoline (ATC: R01AA08) 23 Tramazoline (ATC: R01AA09) 26 Metizoline (ATC: R01AA10) 29 Tuaminoheptane (ATC: R01AA11) 30 Fenoxazoline (ATC: R01AA12) 31 Tymazoline (ATC: R01AA13) 32 Epinephrine (ATC: R01AA14) 33 Indanazoline (ATC: R01AA15) 34 Phenylephrine (ATC: R01AB01) 35 Naphazoline (ATC: R01AB02) 37 Tetryzoline (ATC: R01AB03) 39 Ephedrine (ATC: R01AB05) 40 Xylometazoline (ATC: R01AB06) 41 Oxymetazoline (ATC: R01AB07) 45 Tuaminoheptane (ATC: R01AB08) 46 Cromoglicic Acid (ATC: R01AC01) 49 2 Levocabastine (ATC: R01AC02) 51 Azelastine (ATC: R01AC03) 53 Antazoline (ATC: R01AC04) 56 Spaglumic Acid (ATC: R01AC05) 57 Thonzylamine (ATC: R01AC06) 58 Nedocromil (ATC: R01AC07) 59 Olopatadine (ATC: R01AC08) 60 Cromoglicic Acid, Combinations (ATC: R01AC51) 61 Beclometasone (ATC: R01AD01) 62 Prednisolone (ATC: R01AD02) 66 Dexamethasone (ATC: R01AD03) 67 Flunisolide (ATC: R01AD04) 68 Budesonide (ATC: R01AD05) 69 Betamethasone (ATC: R01AD06) 72 Tixocortol (ATC: R01AD07) 73 Fluticasone (ATC: R01AD08) 74 Mometasone (ATC: R01AD09) 78 Triamcinolone (ATC: R01AD11) 82
    [Show full text]
  • 4. Antibacterial/Steroid Combination Therapy in Infected Eczema
    Acta Derm Venereol 2008; Suppl 216: 28–34 4. Antibacterial/steroid combination therapy in infected eczema Anthony C. CHU Infection with Staphylococcus aureus is common in all present, the use of anti-staphylococcal agents with top- forms of eczema. Production of superantigens by S. aureus ical corticosteroids has been shown to produce greater increases skin inflammation in eczema; antibacterial clinical improvement than topical corticosteroids alone treatment is thus pivotal. Poor patient compliance is a (6, 7). These findings are in keeping with the demon- major cause of treatment failure; combination prepara- stration that S. aureus can be isolated from more than tions that contain an antibacterial and a topical steroid 90% of atopic eczema skin lesions (8); in one study, it and that work quickly can improve compliance and thus was isolated from 100% of lesional skin and 79% of treatment outcome. Fusidic acid has advantages over normal skin in patients with atopic eczema (9). other available topical antibacterial agents – neomycin, We observed similar rates of infection in a prospective gentamicin, clioquinol, chlortetracycline, and the anti- audit at the Hammersmith Hospital, in which all new fungal agent miconazole. The clinical efficacy, antibac- patients referred with atopic eczema were evaluated. In terial activity and cosmetic acceptability of fusidic acid/ a 2-month period, 30 patients were referred (22 children corticosteroid combinations are similar to or better than and 8 adults). The reason given by the primary health those of comparator combinations. Fusidic acid/steroid physician for referral in 29 was failure to respond to combinations work quickly with observable improvement prescribed treatment, and one patient was referred be- within the first week.
    [Show full text]
  • (ACIP) General Best Guidance for Immunization
    8. Altered Immunocompetence Updates This section incorporates general content from the Infectious Diseases Society of America policy statement, 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host (1), to which CDC provided input in November 2011. The evidence supporting this guidance is based on expert opinion and arrived at by consensus. General Principles Altered immunocompetence, a term often used synonymously with immunosuppression, immunodeficiency, and immunocompromise, can be classified as primary or secondary. Primary immunodeficiencies generally are inherited and include conditions defined by an inherent absence or quantitative deficiency of cellular, humoral, or both components that provide immunity. Examples include congenital immunodeficiency diseases such as X- linked agammaglobulinemia, SCID, and chronic granulomatous disease. Secondary immunodeficiency is acquired and is defined by loss or qualitative deficiency in cellular or humoral immune components that occurs as a result of a disease process or its therapy. Examples of secondary immunodeficiency include HIV infection, hematopoietic malignancies, treatment with radiation, and treatment with immunosuppressive drugs. The degree to which immunosuppressive drugs cause clinically significant immunodeficiency generally is dose related and varies by drug. Primary and secondary immunodeficiencies might include a combination of deficits in both cellular and humoral immunity. Certain conditions like asplenia and chronic renal disease also can cause altered immunocompetence. Determination of altered immunocompetence is important to the vaccine provider because incidence or severity of some vaccine-preventable diseases is higher in persons with altered immunocompetence; therefore, certain vaccines (e.g., inactivated influenza vaccine, pneumococcal vaccines) are recommended specifically for persons with these diseases (2,3). Administration of live vaccines might need to be deferred until immune function has improved.
    [Show full text]
  • Approaches for Assessing Health Risks from Complex Mixtures in Indoor Air: a Panel Overview by Carol J
    Environmental Health Perspectives Vol. 95, pp. 135-143, 1991 Approaches for Assessing Health Risks from Complex Mixtures in Indoor Air: A Panel Overview by Carol J. Henry,* Lawrence Fishbein,* William J. Meggs,t Nicholas A. Ashford,' Paul A. Schulte,§ Henry Anderson,/' J. Scott Osborne,' and Daniel W. Sepkovictt Critical to a more definitive human health assessment ofthe potential health risks from exposure to complex mixtures in indoor air is the need for a more definitive clinical measure and etiology ofthe helath effects ofcomplex mixtures. This panel overview highlights six ofthe eight presentations ofthe conference panel discussion and features a number ofthe major topical areas of indoor air concern. W. G. Meggs assessed clinical research priorities with primary focus on the role ofvolatile organic chemicals in human health, recognizing the areas where definitive data are lacking. By recogniz- ing many types ofchemical sensitivity, it may be possible to design studies that can illuminate the mechanisms by which chemical exposure may cause disease. The critically important topic of multiple chemical sensitivity was discussed by N. A. Ashford, who identified four high risk groups and defined the demographics ofthese groups. P. A. Schulte address- ed the issue ofbiological markers ofsusceptibility with specific considerations ofboth methodologia and societal aspects that may be operative in the ability to detect innate or inborne differences between individuals and populations. Three case studies were reviewed. H. Anderson discussed the past and present priorities from a public health perspective, focusing on those issues dealing with exposures to environmental tobacco smoke and formaldehyde off-gassing from materials used in mobile homeconstruction.
    [Show full text]
  • Challenges and Approaches for the Development of Safer Immunomodulatory Biologics
    REVIEWS Challenges and approaches for the development of safer immunomodulatory biologics Jean G. Sathish1*, Swaminathan Sethu1*, Marie-Christine Bielsky2, Lolke de Haan3, Neil S. French1, Karthik Govindappa1, James Green4, Christopher E. M. Griffiths5, Stephen Holgate6, David Jones2, Ian Kimber7, Jonathan Moggs8, Dean J. Naisbitt1, Munir Pirmohamed1, Gabriele Reichmann9, Jennifer Sims10, Meena Subramanyam11, Marque D. Todd12, Jan Willem Van Der Laan13, Richard J. Weaver14 and B. Kevin Park1 Abstract | Immunomodulatory biologics, which render their therapeutic effects by modulating or harnessing immune responses, have proven their therapeutic utility in several complex conditions including cancer and autoimmune diseases. However, unwanted adverse reactions — including serious infections, malignancy, cytokine release syndrome, anaphylaxis and hypersensitivity as well as immunogenicity — pose a challenge to the development of new (and safer) immunomodulatory biologics. In this article, we assess the safety issues associated with immunomodulatory biologics and discuss the current approaches for predicting and mitigating adverse reactions associated with their use. We also outline how these approaches can inform the development of safer immunomodulatory biologics. Immunomodulatory Biologics currently represent more than 30% of licensed The high specificity of the interactions of immu- biologics pharmaceutical products and have expanded the thera- nomodulatory biologics with their relevant immune Biotechnology-derived peutic options available
    [Show full text]
  • BIOLOGIC THERAPIES ASTHMA DYKEWICZ F BW.Pdf
    11/30/2011 Biologic Asthma Therapies and Individualized Medicine Disclosures Advisory boards Mark S. Dykewicz, MD Merck (advisor, honorarium) Director, Allergy & Immunology Shire (advisor, honorarium) Fellowship Program Director Wake Forest University School of Medicine Editorial boards Winston-Salem, North Carolina USA Allergy & Asthma Proceedings American Journal of Rhinology & Allergy Clinical Reviews in Allergy & Immunology Journal of Angioedema Learning Objective Biological therapies May fill unmet needs, potentially in To better understand the use of biologic subpopulations or phenotypes of patients with modifiers in individualized asthma more severe asthma. treatment. May provide insight into mechanisms of asthma Sheharyar, Durrani, Busse. Biological Therapy for Asthma. ACCP PCCSU Article | 03.15.11 Omalizumab (Anti-IgE) Biologics with action against IgE (omalizumab) Biologic mechanism: Mab against IgE; decreases IgE Cytokines levels; results in down-regulation of IgE receptor IL-4 and/or IL-13 Patient subsets: persistent asthma selected for IL-5 specific IgE to perennial allergen, total serum IgE in Chemokine Receptors specified range CCR3 Benefits: 8 trials (n=3429) Rodrigo. Chest 2011 139:28 CXCR2 decreases in exacerbations, dose of inhaled and oral Transcription Factors corticosteroids, hospitalizations PPARs (peroxisome proliferator-activated receptors) improvement in QOL when used as add-on Rx Prostaglandin Receptors no improvement in lung function. CRTH2 6 1 11/30/2011 IL-4 Modifiers IL-13 Altrakincept Solubilized IL-4 Failed to show efficacy in large phase Pleiotropic cytokine of Th2 cells, promotes IgE receptor fragment, 3 trial. production neutralizes IL-4 Adcock et al (2008) May contribute to key features of asthma Pascolizumab Monoclonal Ab Phase 2 study of pascolizumab IL-13 production inhibited by inhaled glucocorticoids against IL- 4 discontinued because of inefficacy.
    [Show full text]
  • Up-Date on Solitary Plasmacytoma and Its Main Differences with Multiple Myeloma P
    Experimental Oncology 27, 7-12, 2005 (March) 7 Exp Oncol 2005 27, 1, 7-12 UP-DATE ON SOLITARY PLASMACYTOMA AND ITS MAIN DIFFERENCES WITH MULTIPLE MYELOMA P. Di Micco1,*, B. Di Micco2 1Thrombosis center, Instituto Clinico Humanitas, Milan, Italy 2Clinical Chemistry, University of Sannio, Benevento, Italy Solitary plasmacytoma is plasma cell neoplasm. It is a localized bone disease and for this reason it is different from multiple myeloma (systemic plasma cell neoplasm). Sometimes, solitary plasmacytoma precedes a following multi- ple myeloma. Clinical findings of solitary plasmacytoma are related to the univocal localization on damaged bone, while laboratory findings could be similar to multiple myeloma (i.e. M component, kidney dysfunction, blood calcium alterations, increased β-2-microglobulin). However, during a solitary plasmacytoma, laboratory findings could not be present contemporaneously such clinical complications (i.e. kidney failure, immunological disorders with a trend toward infectious disease and/or autoimmunity, neurological disorders, haematological disorders, amyloidosis, POEMS syndrome). These raise the reason because solitary plasmacytoma has better prognosis compared to multiple myeloma. Key Words: solitary plasmacytoma, multiple myeloma. General information damages are principally related to light chains and are Plasmacytoma, a clonal neoplastic disorder of bone quickly eliminated representing the Beence-Jones pro- marrow that originates from plasma cells, the last mat- tein in the urine [9, 10]. Moreover, immunoglobulin pro- uration stage of B lymphocytes [1-2], may appear as duced by plasmacytoma may be insoluble if cold tem- three different diseases: multiple myeloma (systemic perature is present, so causing a cryoglobulinemia [5, disease), extramedullary plasmacytoma and solitary 11], in particular if a chronic C viral hepatitis is associ- plasmacytoma (localized bone disease) [3].
    [Show full text]
  • Evidence-Based Practice Center Systematic Review Protocol
    Evidence-based Practice Center Systematic Review Protocol Project Title: Serum-Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias I. Background and Objectives for the Systematic Review Plasma cell dyscrasias (PCDs) are a spectrum of disorders characterized by the expansion of a population of monoclonal bone-marrow plasma cells that produce monoclonal immunoglobulins.1 At the benign end of the spectrum is monoclonal gammopathy of undetermined significance (MGUS), where the plasma-cell clone usually does not expand. Multiple myeloma (MM) is a plasma cell disorder at the malignant end of the spectrum and is characterized by the neoplastic proliferation of a clone of plasma cells in the bone marrow with resulting end-organ damage, including skeletal destruction (lytic bone lesions), hypercalcemia, anemia, and renal insufficiency. Whereas monoclonal plasma cells generally secrete intact immunoglobulin, in about 20 percent of patients with MM these cells only produce light-chain monoclonal proteins (i.e., light-chain multiple myeloma [LCMM], formerly known as Bence Jones myeloma) and in 3 percent of patients they secrete neither light- nor heavy-chain monoclonal proteins that are detectable by immunofixation (i.e., nonsecretory multiple myeloma [NSMM]).1 In two-thirds of patients with NSMM, a monoclonal protein can be identified by the serum-free light chain (SFLC) assay. Patients with LCMM develop complications related to tissue deposition of light chains, including amyloidosis. Amyloid light-chain (AL) amyloidosis is the most common form of systemic amyloidosis seen in the United States and is characterized by a relatively stable, slow-growing plasma-cell clone that secretes light-chain proteins that form Table 1: Diagnostic criteria and clinical course of selected plasma cell dyscrasias (PCDs)2 Disorder Disease Definition Clinical Course Monoclonal gammopathy of .
    [Show full text]
  • Agammaglobulinemia Hypogammaglobulinemia Hereditary Disease Immunoglobulins
    Pediat. Res. 2: 72-84 (1968) Agammaglobulinemia hypogammaglobulinemia hereditary disease immunoglobulins Hereditary Alterations in the Immune Response: Coexistence of 'Agammaglobulinemia', Acquired Hypogammaglobulinemia and Selective Immunoglobulin Deficiency in a Sibship REBECCA H. BUCKLEY[75] and J. B. SIDBURY, Jr. Departments of Pediatrics, Microbiology and Immunology, Division of Immunology, Duke University School of Medicine, Durham, North Carolina, USA Extract A longitudinal immunologic study was conducted in a family in which an entire sibship of three males was unduly susceptible to infection. The oldest boy's history of repeated severe infections be- ginning in infancy and his marked deficiencies of all three major immunoglobulins were compatible with a clinical diagnosis of congenital 'agammaglobulinemia' (table I, fig. 1). Recurrent severe in- fections in the second boy did not begin until late childhood, and his serum abnormality involved deficiencies of only two of the major immunoglobulin fractions, IgG and IgM (table I, fig. 1). This phenotype of selective immunoglobulin deficiency is previously unreported. Serum concentrations of the three immunoglobulins in the youngest boy (who also had a late onset of repeated infection) were normal or elevated when he was first studied, but a marked decline in levels of each of these fractions was observed over a four-year period (table I, fig. 1). We could find no previous reports describing apparent congenital and acquired immunologic deficiencies in a sibship. Repeated infections and demonstrated specific immunologic unresponsiveness preceded gross ab- normalities in the total and fractional gamma globulin levels in both of the younger boys (tables II-IV). When the total immunoglobulin level in the second boy was 735 mg/100 ml, he failed to respond with a normal rise in titer after immunization with 'A' and 'B' blood group substances, diphtheria, tetanus, or Types I and II poliovaccines.
    [Show full text]